Literature DB >> 29168085

Prevalence of Human Papillomavirus Genotypes and Abnormal Pap Smears Among Women in the Military Health System.

Christopher M Daly1,2, Shana L Hansen3, Paul O Kwon4, Timothy A Roberts3.   

Abstract

Human papillomavirus infection (HPV) is the most common sexually transmitted infection among United States Military Servicemembers, and present in the majority of cervical cancers. Many of these infections are preventable, but HPV immunization is not mandatory during military service. The objective of this study was to examine the prevalence of vaccine-preventable cervical disease among women enrolled in the San Antonio Military Health System. This is a retrospective cross-sectional study of Pap smear results and HPV genotyping data among Military Servicewomen and beneficiaries. Simple descriptive statistics and logistic regression were used to assess the association between demographics, cervical pathology and high-risk HPV (hrHPV) infection. Pap smears were obtained by 16.9% of women and cervical pathology was present in 28.8% of samples. Compared to the 25-34 year group, 35-44 year-olds were more likely to have an abnormal Pap smear (OR 1.25, CI 1.05-1.50). Of the samples tested, 10.5% were positive for hrHPV. Adjusted multivariable analysis revealed that hrHPV infection was more likely among the 23-34 year group when compared to 35-44 (OR 0.50, CI 0.38-0.67), 45-54 (0.40. CI 0.28-0.59) and 55-65 year groups (0.46, CI 0.30-0.71). Active Duty Servicewomen were more likely to test positive for hrHPV when compared to Active Duty Family Members (OR 0.59, CI 0.45-0.79) and Retiree Family Members (OR 0.59, CI 0.41-0.83). Younger women and Active Duty Servicewomen are significantly more likely to have cervical infection with hrHPV. Future studies should assess the cost-effectiveness of mandatory HPV immunization for military members.

Entities:  

Keywords:  Human papillomavirus; Military; Pap smear; Sexually transmitted infections

Mesh:

Year:  2018        PMID: 29168085     DOI: 10.1007/s10900-017-0447-z

Source DB:  PubMed          Journal:  J Community Health        ISSN: 0094-5145


  27 in total

1.  Prevalence of HPV After Introduction of the Vaccination Program in the United States.

Authors:  Lauri E Markowitz; Gui Liu; Susan Hariri; Martin Steinau; Eileen F Dunne; Elizabeth R Unger
Journal:  Pediatrics       Date:  2016-02-22       Impact factor: 7.124

2.  Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer.

Authors:  Cosette M Wheeler; William C Hunt; Mark Schiffman; Philip E Castle
Journal:  J Infect Dis       Date:  2006-09-27       Impact factor: 5.226

3.  US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.

Authors:  Mona Saraiya; Elizabeth R Unger; Trevor D Thompson; Charles F Lynch; Brenda Y Hernandez; Christopher W Lyu; Martin Steinau; Meg Watson; Edward J Wilkinson; Claudia Hopenhayn; Glenn Copeland; Wendy Cozen; Edward S Peters; Youjie Huang; Maria Sibug Saber; Sean Altekruse; Marc T Goodman
Journal:  J Natl Cancer Inst       Date:  2015-04-29       Impact factor: 13.506

4.  Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States--National Health And Nutrition Examination Survey, 2003-2006: opportunity to measure HPV vaccine impact?

Authors:  Eileen F Dunne; Maya Sternberg; Lauri E Markowitz; Geraldine McQuillan; David Swan; Sonya Patel; Elizabeth R Unger
Journal:  J Infect Dis       Date:  2011-08-15       Impact factor: 5.226

5.  A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.

Authors:  Elmar A Joura; Anna R Giuliano; Ole-Erik Iversen; Celine Bouchard; Constance Mao; Jesper Mehlsen; Edson D Moreira; Yuen Ngan; Lone Kjeld Petersen; Eduardo Lazcano-Ponce; Punnee Pitisuttithum; Jaime Alberto Restrepo; Gavin Stuart; Linn Woelber; Yuh Cheng Yang; Jack Cuzick; Suzanne M Garland; Warner Huh; Susanne K Kjaer; Oliver M Bautista; Ivan S F Chan; Joshua Chen; Richard Gesser; Erin Moeller; Michael Ritter; Scott Vuocolo; Alain Luxembourg
Journal:  N Engl J Med       Date:  2015-02-19       Impact factor: 91.245

6.  Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer.

Authors:  E L Franco; L L Villa; J P Sobrinho; J M Prado; M C Rousseau; M Désy; T E Rohan
Journal:  J Infect Dis       Date:  1999-11       Impact factor: 5.226

7.  Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study.

Authors:  Monica Molano; Adriaan Van den Brule; Martyn Plummer; Elisabete Weiderpass; Hector Posso; Annie Arslan; Chris J L M Meijer; Nubia Muñoz; Silvia Franceschi
Journal:  Am J Epidemiol       Date:  2003-09-01       Impact factor: 4.897

8.  Genital infections with human papillomavirus (HPV).

Authors:  A B Moscicki
Journal:  Pediatr Infect Dis J       Date:  1998-07       Impact factor: 2.129

9.  Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States.

Authors:  Harrell W Chesson; Donatus U Ekwueme; Mona Saraiya; Meg Watson; Douglas R Lowy; Lauri E Markowitz
Journal:  Vaccine       Date:  2012-08-04       Impact factor: 3.641

10.  Changes in antibody seroprevalence of seven high-risk HPV types between nationwide surveillance studies from 1995-96 and 2006-07 in The Netherlands.

Authors:  Mirte Scherpenisse; Madelief Mollers; Rutger M Schepp; Hein J Boot; Chris J L M Meijer; Guy A M Berbers; Fiona R M van der Klis; Hester E de Melker
Journal:  PLoS One       Date:  2012-11-12       Impact factor: 3.240

View more
  1 in total

1.  Cervical cancer screening compliance among active duty service members in the US military.

Authors:  Julia Seay; Rayna K Matsuno; Ben Porter; Karen Tannenbaum; Steven Warner; Natalie Wells
Journal:  Prev Med Rep       Date:  2022-02-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.